Apotex, a Canadian-based global health firm, announced this week it has received Health Canada approval for Apo-Semaglutide, the first generic equivalent of Ozempic. The generic will be offered in both 2 mg and 4 mg pen formats, signaling a major breakthrough for affordable access. According to Apotex, the move is a commitment to "strengthening access to essential medicines." For patients in Canada, the cost of metabolic health is about to drop. For those across the border in the United States, however, the picture remains one of deep inequality.

In the U.S., more than 18% of adults have tried GLP-1 drugs, but access remains gated by high prices and restrictive insurance. According to a meta-analysis involving 84,000 users, those taking these drugs were 3.4 times more likely to experience hair loss compared to non-users. Dr. Ziyad Al-Aly of WashU Medicine warned that while there is "enormous exuberance" about starting these drugs, there is not nearly enough attention paid to the effects of stopping them. The metabolic health of the American worker is being transformed into a high-priced subscription service, one that carries physical risks that are often downplayed by corporate marketing.

This paper identifies a growing "Metabolic Divide." On one side of the border, a generic version offers a glimpse of medicine as a public good; on the other, it remains a Veblen good—a luxury item whose price signals status. The enclosure of the human body by pharmaceutical patents is the ultimate frontier of capital. When the ability to maintain a healthy weight is gated by citizenship and credit scores, the state has effectively abandoned its duty to the physical welfare of its people. The generic approval in Canada is a small victory for the commons, but the systemic enclosure of health remains the dominant reality for the global working class.